Literature DB >> 24418723

Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).

Antonio Gonzalez-Martin1, Laurence Gladieff2, Bengt Tholander3, Daniel Stroyakovsky4, Martin Gore5, Giovanni Scambia6, Ana Oaknin7, Vesna Sneller8, Ulrich Freudensprung8, Sandro Pignata9.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24418723     DOI： 10.1016/j.ejca.2013.12.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.

Authors:  Caroline Lum; Christopher B Steer
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

Review 2.  Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.

Authors:  Carolyn E Haunschild; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2019-11-20       Impact factor: 3.404

Review 3.  Improving outcomes for older women with gynaecological malignancies.

Authors:  Lucy Dumas; Alistair Ring; John Butler; Tania Kalsi; Danielle Harari; Susana Banerjee
Journal:  Cancer Treat Rev       Date:  2016-08-29       Impact factor: 12.111
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.